Supplementary Table 1. Baseline Characteristics of the Study Population according to the Intensity of Statin Therapy after Propensity Score Matching

Variables	LMI (n=238)	HI (n=79)	p value	SD	LMI (n=225)	HI (n=227)	p value	SD
Age (yr)	71±10	68±11	0.088	2.13	71±10	71±19	0.088	0.35
Male	175 (73.5)	64 (81.0)	0.181	0.08	164 (72.9)	170 (74.8)	0.644	0.09
Current smoker	79 (33.2)	32 (40.5)	0.238	0.04	73 (32.4)	81 (35.6)	0.473	0.02
Critical limb ischemia	89 (37.4)	23 (29.1)	0.182	-0.08	86 (38.2)	96 (42.4)	0.371	0
Hypertension	187 (78.6)	52 (65.8)	0.023	-0.01	178 (79.1)	168 (74.2)	0.217	-0.12
Diabetes	128 (53.8)	36 (45.6)	0.206	-0.07	123 (54.7)	127 (55.9)	0.795	-0.06
Dyslipidemia	23 (9.7)	6 (7.6)	0.580	-0.02	23 (10.2)	22 (9.5)	0.791	0
Congestive heart failure	31 (13.0)	7 (8.9)	0.323	-0.05	30 (13.3)	25 (11.0)	0.455	0.01
Chronic kidney disease	66 (27.7)	21 (26.6)	0.843	0.01	62 (27.6)	66 (29.1)	0.719	-0.03
Coronary artery disease	122 (51.3)	38 (48.1)	0.627	0.02	116 (51.6)	116 (51.1)	0.896	-0.04
Stroke	51 (21.4)	10 (12.7)	0.087	-0.07	49 (21.8)	59 (25.9)	0.309	-0.06
RAAS-blocker	112 (47.1)	31 (39.2)	0.226	-0.11	109 (48.4)	111 (48.9)	0.926	-0.07
Beta-blocker	93 (39.1)	29 (36.7)	0.708	0.01	90 (40.0)	70 (30.8)	0.042	0
DAPT duration over 6 months	43 (54.4)	112 (47.1)	0.256	0.11	106 (47.1)	99 (43.6)	0.458	-0.03
Body mass index (kg/m^2)	23±3.6	23±4.2	0.493	0.10	23.2±3.6	22.3±0.7	0.493	-0.08
Hemoglobin (g/dL)	12.2±2.1	12.3±2.1	0.475	-0.07	12.2±2.1	12.1±3.7	0.475	-0.17
Albumin (g/dL)	3.8±0.6	3.8±0.4	0.705	0.01	3.8±0.6	3.8±0.9	0.705	0
Target LDL <70 mg/dL	88 (37.4)	37 (46.8)	0.127	-0.12	84 (37.3)	86 (37.7)	0.934	0
TASC classification C or D	122 (51.3)	39 (49.4)	0.745	0.03	115 (51.1)	115 (50.6)	0.912	-0.04
Below knee lesion	72 (30.3)	19 (24.1)	0.291	-0.04	67 (29.7)	72 (31.7)	0.647	-0.06

DAPT, dual antiplatelet therapy; HI high-intensity; LDL, low-density lipoprotein; LMI, low-to-moderate intensity; RAAS, renin angiotensin aldosterone system; SD, standardized difference; TASC, Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease.
Data are presented as mean±SD or n (%).